Effectiveness and Safety of Direct-Acting Antivirals in Treating Chronic Hepatitis C
Author Information
Author(s): Hyppolito Elodie Bomfim, Ramos Alberto Novaes Jr, Teixeira Larissa Peixoto, Bezerra Arthur Machado, Mendes Lucas Arruda, Silva Taynara Lais, Lima José Milton de Castro, de Arruda Érico Antonio Gomes, Guerra Eder Janes, Tavares Maria Macedo Saraiva, Lima Carlos Eduardo Pereira, Esmeraldo Ticiana Mota, Pessoa Francisco Sérgio Rangel de Paula, Pierre Alessandra Maria Montalverne, Pereira Karla Brandão, Araújo Antônio Haroldo Filho, Linhares Lívia Melo Carone, Ferreira Anderson Fuentes, Pires Roberto da Justa Neto
Primary Institution: Universidade Federal do Ceará
Hypothesis
This study aimed to evaluate the effectiveness and safety of direct-acting antivirals (DAAs) for hepatitis C treatment by measuring sustained virologic response (SVR) and serious adverse events.
Conclusion
DAA treatment for hepatitis C achieved a high cure rate in various patient profiles, although some patients with cirrhosis experienced serious adverse events.
Supporting Evidence
- 96.4% of patients achieved sustained virologic response (SVR).
- Serious adverse events occurred in 3.5% of patients.
- Patients with cirrhosis had a lower SVR rate of 93.4% compared to 97.9% in those with less severe fibrosis.
- Most patients experienced mild and transient adverse events.
- Nine patients died during treatment, primarily those with cirrhosis.
Takeaway
This study shows that most people treated for hepatitis C with new medicines got better, but some had serious problems, especially those with liver damage.
Methodology
This was a retrospective, observational study analyzing data from patients treated with DAAs for hepatitis C in Ceará, Brazil, using statistical tests to evaluate outcomes.
Potential Biases
Potential bias due to the retrospective nature of the study and reliance on medical records.
Limitations
The study may not fully represent patients from rural areas, as most participants were from the capital.
Participant Demographics
Mean age was 56.6 years, with 60.2% men; included HIV-infected patients and liver transplant recipients.
Statistical Information
P-Value
0.0015
Statistical Significance
p=0.0015
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website